[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BioBoyScout Avatar @BioBoyScout BioBoyScout

BioBoyScout posts on X about $arwr, science, $41b, $alny the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXXX% finance XXXX%

Social topic influence $arwr #2, science 9.52%, $41b 9.52%, $alny 4.76%, $ions 4.76%, $arwrs 4.76%, flows 4.76%, bearish 4.76%, math 4.76%, compound XXXX%

Top accounts mentioned or mentioned by @superduperdrugs @ttramyloid @frankhulskof @drfager @leftyt75 @biomedicalrx @longroaderstar @j6_a12 @wallstlobo

Top assets mentioned Arrowhead Research Corporation (ARWR) Alnylam Pharmaceuticals, Inc. (ALNY) Ionis Pharmaceuticals, Inc. Common Stock (IONS)

Top Social Posts

Top posts by engagements in the last XX hours

"9/10 Thats why $ARWR is totally miscomped. The right peers are $ALNY and $IONS platforms that repeatedly generate drugs and earn higher multiples"
X Link 2025-12-09T18:41Z 4024 followers, 1183 engagements

"Dropping a new note on why sell-side keeps undervaluing $ARWR. TRiMs multi-tissue reach best-in-class science and massive pipeline optionality arent in their models. Arrowheads real Enterprise Value is far higher a $41B+ MC is now justified"
X Link 2025-11-26T13:22Z 4012 followers, 12.7K engagements

"1/8 New analysis out: a Monte Carlo sim comparing plozasiran vs olezarsen shows REDEMPLO drives deeper & more reliable TG reductions across all scenarios. Thats a major win for $ARWR & a sign the Street is still underestimating TRiMs clinical consistency"
X Link 2025-12-04T20:01Z 4012 followers, 2018 engagements

"7/8 Lastly dont ignore $ARWR's partnership leverage. Better efficacy higher milestone capture + stronger royalty economics across Takeda Amgen GSK and Sarepta programs. This is nowhere in consensus numbers"
X Link 2025-12-04T20:01Z 4014 followers, 1100 engagements

"6/10 Extrahepatic RNAi is still mispriced for $ARWR. Sarepta validating both muscle and pulmonary TRiM is huge. Thats not high risk science thats pharma-level validation"
X Link 2025-12-09T18:41Z 4020 followers, XXX engagements

"7/10 $ARWR partnerships get modeled by BofA as cash flows only. Missing: Takeda Amgen GSK Sarepta all de-risk the platform. That should lift PoS speed and EV across the pipeline"
X Link 2025-12-09T18:41Z 4021 followers, XXX engagements

"10/ Bottom line: the BofA note on $ARWR isnt bearish its incomplete. Add platform reuse PoS uplift extrahepatic scale and intangible EV and a $41B valuation isnt aggressive. Its simple clean math and it's about time"
X Link 2025-12-09T18:41Z 4024 followers, 1055 engagements

"8/10 Time horizon bias. Platform biotechs compound for decades not one product cycle. Truncate the long tail and youll always undervalue the business. $ARWR"
X Link 2025-12-09T18:41Z 4024 followers, XXX engagements

"ARO-MAPT may be the most important readout in $ARWR history. First SC systemic BBB-penetrant RNAi platform. Deep KD across cortex brainstem spinal cord. Durable 3+ months. 10x safety. CTA filed. Opens CNS the largest unmet space in all of medicine. Easily a $1015B premium"
X Link 2025-12-11T14:58Z 4024 followers, 2190 engagements